Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Morphosys Ag ADR
(NQ:
MOR
)
18.96
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Aug 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Morphosys Ag ADR
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022
April 28, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
MorphoSys AG
Via
AccessWire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
March 24, 2022
Gainers BiondVax Pharmaceuticals (NASDAQ:BVXV) shares moved upwards by 55.5% to $2.13 during Thursday's pre-market session. The market value of their outstanding...
Via
Benzinga
The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale
March 23, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
MorphoSys-Incyte Partnered Minjuvi Temporarily Approved In Switzerland
March 23, 2022
The
Via
Benzinga
MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL
March 22, 2022
MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell...
From
MorphoSys AG
Via
AccessWire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
March 22, 2022
Gainers Palisade Bio (NASDAQ:PALI) stock rose 59.0% to $1.28 during Tuesday's pre-market session. The company's market cap stands at $23.3 million. As per the news...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
March 22, 2022
Grab your cup of coffee, investor! We're starting off the day with a dive into the biggest pre-market stock movers for Tuesday!
Via
InvestorPlace
MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 16, 2022
From
MorphoSys AG
Via
Business Wire
Earnings Scheduled For March 16, 2022
March 16, 2022
Companies Reporting Before The Bell • Ideanomics (NASDAQ:IDEX) is likely to report quarterly loss at $0.05 per share on revenue of $33.20 million. • Tarena...
Via
Benzinga
National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in Its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
March 15, 2022
BOSTON, MA / ACCESSWIRE / March 15, 2022 / MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE:MOR)(NASDAQ:MOR), announced today that the National Comprehensive Cancer Network(R) (NCCN)...
From
MorphoSys AG
Via
AccessWire
Earnings Outlook For MorphoSys
March 15, 2022
MorphoSys (NASDAQ:MOR) is set to give its latest quarterly earnings report on Wednesday, 2022-03-16. Here's what investors need to know before the announcement. Analysts estimate...
Via
Benzinga
Invitation to MorphoSys' Full Year Results 2021 Conference Call on March 17, 2022
March 10, 2022
Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 10, 2022 / MorphoSys AG (FSE:MOR);(NASDAQ:MOR) will publish its results for the financial year 2021 on March 16, 2022 at 9:00 pm...
From
MorphoSys AG
Via
AccessWire
MorphoSys Discontinues US Discovery Activities, Takes €231M Impairment Charge
March 10, 2022
MorphoSys AG (NASDAQ: MOR) has reported a non-cash impairment charge of €231 million on goodwill after consolidating research and discovery functions. This...
Via
Benzinga
MorphoSys AG Reports Non-Cash Impairment Charge of € 231 Million on Goodwill After Consolidation of Research and Discovery Functions; Corresponding Increase of Group Operating Expenses in 2021
March 10, 2022
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2014 PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 10, 2022 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR)...
From
MorphoSys AG
Via
AccessWire
MorphoSys ranked Number One in Germany for Female Representation at Leadership Level in European Women on Boards' Gender Equality Index Report
January 24, 2022
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 24, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) was acknowledged as a Best Practice Leader in the European Women on Boards' Gender Equality Index Report,...
From
MorphoSys AG
Via
AccessWire
Stocks That Hit 52-Week Lows On Friday
February 18, 2022
On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week...
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
February 17, 2022
On Thursday, 147 companies achieved new lows for the year. Significant Points From Today's 52-Week Lows: PayPal Holdings (NASDAQ:PYPL) was the biggest company...
Via
Benzinga
MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
January 18, 2022
- Preliminary 2021 Monjuvi U.S. net product sales of US$ 79.1 million ( € 66.9 million) - Anticipated 2022 Monjuvi U.S. net product sales in the range of US$ 110 to 135 million PLANEGG / MUNICH,...
From
MorphoSys AG
Via
AccessWire
Benzinga's Top Ratings Upgrades, Downgrades For January 14, 2022
January 14, 2022
Upgrades According to Seaport Global, the prior rating for Lennar Corp (NYSE:
Via
Benzinga
MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference
January 10, 2022
PLANEGG / MUNICH, GERMANY / ACCESSWIRE / Janauary 10, 2022 / MorphoSys AG (FSE:MOR; NASDAQ:MOR), announced today that Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys, will present at the 40...
From
MorphoSys AG
Via
AccessWire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
January 06, 2022
Gainers Freeline Therapeutics (NASDAQ:FRLN) stock increased by 58.1% to $3.1 during Thursday's pre-market session. The company's market cap stands at $111.0...
Via
Benzinga
20 Stocks Moving in Wednesday's Pre-Market Session
December 22, 2021
Gainers BioRestorative Therapies, Inc. (NASDAQ: BRTX) rose 48.1% to $6.77 in pre-market trading after the company entered into a Master Service Agreement with PRC Clinical,...
Via
Benzinga
MorphoSys Presents Latest Data from the Phase 2 MANIFEST Study Evaluating the Potential of Pelabresib in the Treatment of Myelofibrosis
December 12, 2021
MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis - Data presented during poster and oral sessions at the 63rd...
From
MorphoSys AG
Via
AccessWire
MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
December 11, 2021
- RE-MIND2 compared patient outcomes from pivotal L-MIND study with matched patient populations treated with NCCN/ESMO recommended therapies - Results from the retrospective cohort analysis indicate...
From
MorphoSys AG
Via
AccessWire
Exposures
COVID-19
Product Safety
MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
December 11, 2021
From
Incyte
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
December 10, 2021
Gainers Reshape Lifesciences (NASDAQ:RSLS...
Via
Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
December 06, 2021
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...
Via
Benzinga
Exposures
Product Safety
Corporate Calendar 2022
November 29, 2021
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 29, 2021 / Corporate Calendar 2022 Dear Madam/Sir, Please note MorphoSys' financial reporting dates 2022 as follows: Publication of Interim Statement /...
From
MorphoSys AG
Via
AccessWire
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 22, 2021
Gainers iSpecimen (NASDAQ:ISPC) stock rose 31.09% to $6.45 during Monday's pre-market session. The company's market cap stands at $44.9 million. Provention Bio (...
Via
Benzinga
MorphoSys AG (MOR) Q3 2021 Earnings Call Transcript
November 11, 2021
MOR earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.